Related content

Ii-Key/HER-2/neu(776–790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

By Sotiriadou Nectaria   Kallinteris Nikoletta   Gritzapis Angelos   Voutsas Ioannis   Papamichail Michael   Hofe Eric   Humphreys Robert   Pavlis Theodoros   Perez Sonia   Baxevanis Constantin  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 5, 2007-05 ,pp. : 601-613

Springer Publishing Company

Access to resources Recommend Favorite

Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine

By Hueman Matthew   Stojadinovic Alexander   Storrer Catherine   Dehqanzada Zia   Gurney Jennifer   Shriver Craig   Ponniah Sathibalan   Peoples George  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 2, 2007-02 ,pp. : 135-146

Springer Publishing Company

Access to resources Recommend Favorite

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer

By Gillogly Michael   Kallinteris Nikoletta   Xu Minzhen   Gulfo Joseph   Humphreys Robert   Murray James  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 6, 2004-06 ,pp. : 490-496

Springer Publishing Company

Access to resources Recommend Favorite

Testing to Define the Target Her-2/neu

By Menard Sylvie  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 63-66

Springer Publishing Company

Access to resources Recommend Favorite

Identification of HER2/neu-Derived Peptides Capable of Inducing both Cellular and Humoral Immune Responses in HLA-A24 Positive Breast Cancer Patients

By Azuma Koichi   Shichijo Shigeki   Shomura Hiroki   Matsueda Satoko   Fujii Teruhiko   Itoh Kyogo  

Breast Cancer Research and Treatment, Vol. 86, Iss. 1, 2004-07 ,pp. : 19-29

Springer Publishing Company

Access to resources Recommend Favorite